Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD45RA-depleted peripheral blood mononuclear cells are a specialized cellular therapy product created by selectively removing CD45RA-positive cells (primarily naive T cells) from donor peripheral blood mononuclear cells (PBMCs), resulting in a preparation enriched with memory T cells that can fight infections while reducing the risk of graft-versus-host disease (GVHD). ## Description CD45RA-depleted peripheral blood mononuclear cells are a cellular therapy product created through immunomagnetic depletion of CD45RA-positive cells from donor peripheral blood mononuclear cells. This selective depletion process removes naive T cells (TN) while preserving memory T cells (TM) that have specificity for common opportunistic pathogens[1][6]. The resulting cellular product contains a high amount of memory T cells that can provide protection against viral infections (such as cytomegalovirus, Epstein-Barr virus, and adenovirus) and fungal infections (such as Aspergillus)[5][7]. This approach has been shown to enhance early T-cell recovery and significantly reduce both the incidence and duration of viremia in transplant recipients[1]. The depletion process is performed using GMP-grade murine αCD45RA monoclonal antibody directly conjugated to Miltenyi iron dextran beads, which allows for the selective removal of CD45RA+ cells while preserving CD34+ hematopoietic stem cells and functional memory T cells[7]. Clinical studies have demonstrated that recipients of CD45RA-depleted grafts had significantly higher T-cell counts at Day +30 post-transplant (550/μL vs 10/μL) and higher T-cell diversity compared to recipients of conventional T-cell depleted grafts[1]. This approach has been particularly valuable in the context of haploidentical hematopoietic cell transplantation, where it provides a safer alternative to conventional T-cell depletion methods[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CD45RA-depleted peripheral blood mononuclear cells.